vs
Side-by-side financial comparison of Phreesia, Inc. (PHR) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
Phreesia, Inc. is the larger business by last-quarter revenue ($120.3M vs $66.0M, roughly 1.8× SOLENO THERAPEUTICS INC). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 3.5%, a 35.9% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $12.2M).
Phreesia, Inc. is a software as a service company that offers healthcare organizations a set of applications to automate and manage patient intake.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
PHR vs SLNO — Head-to-Head
Income Statement — Q3 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $120.3M | $66.0M |
| Net Profit | $4.3M | $26.0M |
| Gross Margin | — | 98.3% |
| Operating Margin | 3.1% | 33.5% |
| Net Margin | 3.5% | 39.4% |
| Revenue YoY | 12.7% | — |
| Net Profit YoY | 129.7% | 134.0% |
| EPS (diluted) | $0.07 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $120.3M | — | ||
| Q3 25 | $117.3M | $66.0M | ||
| Q2 25 | $115.9M | $32.7M |
| Q4 25 | $4.3M | — | ||
| Q3 25 | $654.0K | $26.0M | ||
| Q2 25 | $-3.9M | $-4.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% |
| Q4 25 | 3.1% | — | ||
| Q3 25 | -1.3% | 33.5% | ||
| Q2 25 | -2.8% | -20.0% |
| Q4 25 | 3.5% | — | ||
| Q3 25 | 0.6% | 39.4% | ||
| Q2 25 | -3.4% | -14.4% |
| Q4 25 | $0.07 | — | ||
| Q3 25 | $0.01 | $0.47 | ||
| Q2 25 | $-0.07 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $106.4M | $498.9M |
| Total DebtLower is stronger | $3.4M | — |
| Stockholders' EquityBook value | $320.3M | $494.8M |
| Total Assets | $423.5M | $599.9M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $106.4M | — | ||
| Q3 25 | $98.3M | $498.9M | ||
| Q2 25 | $90.9M | $286.8M |
| Q4 25 | $3.4M | — | ||
| Q3 25 | $4.6M | — | ||
| Q2 25 | $6.2M | — |
| Q4 25 | $320.3M | — | ||
| Q3 25 | $298.0M | $494.8M | ||
| Q2 25 | $282.2M | $240.1M |
| Q4 25 | $423.5M | — | ||
| Q3 25 | $408.6M | $599.9M | ||
| Q2 25 | $400.4M | $332.3M |
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.02× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.5M | $43.5M |
| Free Cash FlowOCF − Capex | $12.2M | $43.5M |
| FCF MarginFCF / Revenue | 10.1% | 65.8% |
| Capex IntensityCapex / Revenue | 2.7% | 0.0% |
| Cash ConversionOCF / Net Profit | 3.62× | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.5M | — | ||
| Q3 25 | $14.8M | $43.5M | ||
| Q2 25 | $14.8M | $-12.6M |
| Q4 25 | $12.2M | — | ||
| Q3 25 | $13.1M | $43.5M | ||
| Q2 25 | $11.3M | $-12.6M |
| Q4 25 | 10.1% | — | ||
| Q3 25 | 11.1% | 65.8% | ||
| Q2 25 | 9.8% | -38.6% |
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.5% | 0.0% | ||
| Q2 25 | 3.0% | 0.0% |
| Q4 25 | 3.62× | — | ||
| Q3 25 | 22.68× | 1.67× | ||
| Q2 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PHR
| Subscription And Services | $55.5M | 46% |
| Network Solutions | $37.4M | 31% |
| Payment Processing Fees | $27.4M | 23% |
SLNO
Segment breakdown not available.
